Astex Pharmaceuticals, Inc.

Subsidiary of Otsuka Holdings (4578)

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
AKT (inhibitor)Small molecule
Breast CancerProstate Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
November 2027 (2)
CapivasertibPhase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
CapivasertibPhase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-11-30 · NCT06764186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.